CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Lixte Biotechnology Holdings Welcomes Gil N Schwartzberg

Life Sciences Review Life Sciences Review | Wednesday, April 28, 2021
Tweet

Gil N Schwartzberg comes to Lixte Biotechnology Holdings.


FREMONT, CA: Lixte Biotechnology Holdings, a clinical-stage drug discovery firm that is developing pharmacologically active drugs for use in cancer treatment announces Gil N Schwartzberg's appointment to its Board of Directors. Mr. Schwartzberg is filling a vacancy generated by the resignation of Winson (Sze Chun) Ho, M.D. Gil Schwartzberg has played an essential role in advising and helping Lixte since its inception. The company is pleased to be welcoming Mr. Schwartzberg to the Board of Directors.


Dr. Ho leaves the Lixte Board of Directors to focus his expertise on clinical and pre-clinical cancer research in academic medicine. Dr. Ho has led Lixte with distinction, and the company wishes him great success in his future endeavors.


Gil N Schwartzberg has been a consultant to Lixte since its founding. Previously, Mr. Schwartzberg was Chairman of the Board, President, and CEO of the City of Hope National Medical Center, a leading biomedical research and treatment facilities and an NCI Comprehensive Cancer Center. Mr. Schwartzberg is a person in the hundred-plus-year history of the City of Hope to have led as both Chairman of the Board and CEO. Mr. Schwartzberg is City of Hope Chairman Emeritus for life now.


Before joining the City of Hope, Mr. Schwartzberg was Vice Chairman of the Board of Directors of Sterling Bank of Los Angeles, of which he was a founder, and where he served for several years as the Chairman of the Loan Committee until the banks' sale. Besides, Mr. Schwartzberg was a founding shareholder of Skechers USA, Inc. Mr. Schwartzberg is a consultant to Skechers and both trustee and co-trustee of trusts that hold the controlling interest in Skechers.


Mr. Schwartzberg secured a Juris Doctorate awarded magna cum laude. Mr. Schwartzberg practiced law, specializing in business structure and transactions, and is a member in good standing of the California Bar. Mr. Schwartzberg is the author of books like Warning! Toxic Business Mistakes and How to Avoid Making Them and Jane Austen's Persuasion Annotated, a Royal Navy Reading Companion.


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/lixte-biotechnology-holdings-welcomes-gil-n-schwartzberg-nwid-341.html